Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly

European Urology

Volumn 66, Issue 5, 2014, Pages 841-848

  Bhindi, Bimal ^a   Kulkarni, Girish S ^a,b   Finelli, Antonio ^a   Alibhai, Shabbir M H ^a   Hamilton, Robert J ^a   Toi, Ants ^a   Van Der Kwast, Theodorus H ^a   Evans, Andrew ^a   Hersey, Karen ^a   Jewett, Michael A S ^a   Zlotta, Alexandre R ^a   Trachtenberg, John ^a   Fleshner, Neil E ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Active surveillance; Obesity; Prostatic neoplasms; Watchful waiting

Indexed keywords

ADULT; ARTICLE; BODY MASS; CANCER GROWTH; COHORT ANALYSIS; DISEASE ASSOCIATION; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; AGED; BIOPSY; CANADA; CANCER GRADING; CANCER STAGING; COMPLICATION; DISEASE COURSE; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTOR; TIME; WATCHFUL WAITING;

AGED; BIOPSY; BODY MASS INDEX; DISEASE PROGRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; OBESITY; ONTARIO; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; WATCHFUL WAITING;

EID: 84946238696     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.06.005     Document Type: Article

References (30)

1. L. Klotz, L. Zhang, A. Lam, R. Nam, A. Mamedov, A. Loblaw Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer J Clin Oncol 28 2010 126 131
2. E.H. Allott, E.M. Masko, S.J. Freedland Obesity and prostate cancer: weighing the evidence Eur Urol 63 2013 800 809
3. S.D. Hursting, M.J. Hursting Growth signals, inflammation, and vascular perturbations: mechanistic links between obesity, metabolic syndrome, and cancer Arterioscler Thromb Vasc Biol 32 2012 1766 1770
4. A. Discacciati, N. Orsini, A. Wolk Body mass index and incidence of localized and advanced prostate cancer - a dose-response meta-analysis of prospective studies Ann Oncol 23 2012 1665 1671
5. Y. Cao, J. Ma Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis Cancer Prev Res (Phila) 4 2011 486 501
6. E.E. Calle, C. Rodriguez, K. Walker-Thurmond, M.J. Thun Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults N Engl J Med 348 2003 1625 1638
7. M.E. Wright, S.C. Chang, A. Schatzkin et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality Cancer 109 2007 675 684
8. L.L. Banez, R.J. Hamilton, A.W. Partin et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer JAMA 298 2007 2275 2280
9. D.I. Chu, C. De Nunzio, L. Gerber et al. Predictive value of digital rectal examination for prostate cancer detection is modified by obesity Prostate Cancer Prostatic Dis 14 2011 346 353
10. S.J. Freedland, E.A. Platz, J.C. Presti et al. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection J Urol 175 2006 500 504
11. B. Bhindi, D. Margel, G. Trottier et al. Obesity is associated with larger prostate volume but not with worse urinary symptoms: analysis of a large multiethnic cohort Urology 83 2014 81 87
12. Bhindi B, Locke J, Alibhai SM, et al. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.01.040
13. E. Vittinghoff, C.E. McCulloch Relaxing the rule of ten events per variable in logistic and Cox regression Am J Epidemiol 165 2007 710 718
14. S.J. Freedland, C.J. Kane, C.L. Amling et al. Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications Urology 69 2007 495 499
15. G. Ploussard, A. de la Taille, Y. Bayoud et al. The risk of upstaged disease increases with body mass index in low-risk prostate cancer patients eligible for active surveillance Eur Urol 61 2012 356 362
16. M. Truong, J.A. Slezak, C.P. Lin et al. Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer Cancer 119 2013 3992 4002
17. C.J. Kane, R. Im, C.L. Amling et al. Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database Urology 76 2010 695 700
18. N.M. Corcoran, C.M. Hovens, M.K. Hong et al. Underestimation of Gleason score at prostate biopsy reflects sampling error in lower volume tumours BJU Int 109 2012 660 664
19. M. Ketchandji, Y.F. Kuo, V.B. Shahinian, J.S. Goodwin Cause of death in older men after the diagnosis of prostate cancer J Am Geriatr Soc 57 2009 24 30
20. P.L. Nguyen, J. Ma, J.E. Chavarro et al. Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival J Clin Oncol 28 2010 3958 3964
21. A. Pettersson, R.T. Lis, A. Meisner et al. Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG J Natl Cancer Inst 105 2013 1881 1890
22. F.H. Schroder, J. Hugosson, M.J. Roobol et al. Prostate-cancer mortality at 11 years of follow-up N Engl J Med 366 2012 981 990
23. G.L. Lu-Yao, P.C. Albertsen, D.F. Moore et al. Outcomes of localized prostate cancer following conservative management JAMA 302 2009 1202 1209
24. Y.H. Shao, P.C. Albertsen, C.B. Roberts et al. Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml Arch Intern Med 170 2010 1256 1261
25. N.E. Fleshner, M.S. Lucia, B. Egerdie et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial Lancet 379 2012 1103 1111
26. A. Finelli, G. Trottier, N. Lawrentschuk et al. Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancer Eur Urol 59 2011 509 514
27. G.L. Andriole, D.G. Bostwick, O.W. Brawley et al. Effect of dutasteride on the risk of prostate cancer N Engl J Med 362 2010 1192 1202
28. I.M. Thompson, P.J. Goodman, C.M. Tangen et al. The influence of finasteride on the development of prostate cancer N Engl J Med 349 2003 215 224
29. D. Margel, D.R. Urbach, L.L. Lipscombe et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes J Clin Oncol 31 2013 3069 3075
30. E.M. Masko, E.H. Allott, S.J. Freedland The relationship between nutrition and prostate cancer: is more always better? Eur Urol 63 2013 810 820